HK1211027A1 - Pyrrolotriazinone derivatives as pi3k inhibitors - Google Patents

Pyrrolotriazinone derivatives as pi3k inhibitors Download PDF

Info

Publication number: HK1211027A1
Authority: HK; Hong Kong
Prior art keywords: pi3k inhibitors; pyrrolotriazinone derivatives; pyrrolotriazinone; derivatives; inhibitors
Prior art date: 2012-10-16

Application number

HK15111815.3A

Other languages

English (en)

Chinese (zh)

Inventor

Montserrat Erra Sola

Marta Carrascal Riera

Joan Taltavull Moll

Javalo Caturla

Francisco Javier Bernal Anchuela

Lluis Miquel Pages Santacana

Mart Mir Cepeda

Maria Begona Hernandez Olasagarre

Original Assignee

Almirall, S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-10-16

Filing date

2013-10-15

Publication date

2016-05-13

2013-10-15 Application filed by Almirall, S.A. filed Critical Almirall, S.A.

2016-05-13 Publication of HK1211027A1 publication Critical patent/HK1211027A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Hematology (AREA)
Oncology (AREA)
Obesity (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Physical Education & Sports Medicine (AREA)
Virology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Otolaryngology (AREA)
Communicable Diseases (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

HK15111815.3A 2012-10-16 2013-10-15 Pyrrolotriazinone derivatives as pi3k inhibitors HK1211027A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP12382399.9		2012-10-16
EP12382399		2012-10-16
US201261718782P	2012-10-26	2012-10-26
US61/718,782		2012-10-26
PCT/EP2013/071551 WO2014060432A1 (en)	2012-10-16	2013-10-15	Pyrrolotriazinone derivatives as pi3k inhibitors

Publications (1)

Publication Number	Publication Date
HK1211027A1 true HK1211027A1 (en)	2016-05-13

Family

ID=47049114

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK15111815.3A HK1211027A1 (en)	2012-10-16	2013-10-15	Pyrrolotriazinone derivatives as pi3k inhibitors

Country Status (29)

Country	Link
US (1)	US9388189B2 (xx)
EP (1)	EP2909207A1 (xx)
JP (1)	JP2015533181A (xx)
KR (1)	KR20150068953A (xx)
CN (1)	CN104854108A (xx)
AP (1)	AP2015008328A0 (xx)
AR (1)	AR093036A1 (xx)
AU (1)	AU2013333938A1 (xx)
BR (1)	BR112015007231A2 (xx)
CA (1)	CA2883426A1 (xx)
CL (1)	CL2015000956A1 (xx)
CR (1)	CR20150175A (xx)
DO (1)	DOP2015000077A (xx)
EA (1)	EA027277B1 (xx)
GE (1)	GEP201706623B (xx)
GT (1)	GT201500094A (xx)
HK (1)	HK1211027A1 (xx)
IL (1)	IL237475A0 (xx)
MD (1)	MD20150048A2 (xx)
MX (1)	MX2015004327A (xx)
NI (1)	NI201500054A (xx)
PE (1)	PE20150637A1 (xx)
PH (1)	PH12015500813A1 (xx)
SG (1)	SG11201502032VA (xx)
TN (1)	TN2015000112A1 (xx)
TW (1)	TW201429975A (xx)
UY (1)	UY35086A (xx)
WO (1)	WO2014060432A1 (xx)
ZA (1)	ZA201501220B (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014015523A1 (en) *	2012-07-27	2014-01-30	Hutchison Medipharma Limited	Novel heteroaryl and heterocycle compounds, compositions and methods
US9682083B2 (en) *	2013-05-14	2017-06-20	Nerviano Medical Sciences S.R.L.	Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
JP6494633B2 (ja)	2013-09-22	2019-04-03	キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒＳｃｉｅｎｃｅｓ，Ｌｌｃ	置換されているアミノピリミジン化合物および使用方法
JP6291601B2 (ja)	2014-07-04	2018-03-14	ルピン・リミテッド	Ｐｉ３ｋ阻害剤としてのキノリジノン誘導体
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2016202800A1 (en)	2015-06-16	2016-12-22	Almirall, S.A.	Pyrrolotriazinone derivatives as pi3k inhibitors
CN106467545B (zh) *	2015-08-20	2018-10-16	北大方正集团有限公司	一种噻吩并嘧啶化合物
WO2017076990A1 (en)	2015-11-05	2017-05-11	Almirall, S.A.	Addition salts of n-[4-(4-{[(1s)-1-(5-methyl-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)ethyl]amino}-7h-pyrrolo[2,3-d]pyrimidin-5-yl)-1h-indol-6-yl]sulfamide
EP3371221A2 (en)	2015-11-07	2018-09-12	MultiVir Inc.	Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
DK3377495T3 (da)	2015-11-16	2022-05-09	Topadur Pharma Ag	2-phenyl-3,4-dihydropyrrolo[2,1-f] [1,2,4]triazinon-derivativer som phosphodiesterasehæmmere og anvendelser deraf
US9630968B1 (en)	2015-12-23	2017-04-25	Arqule, Inc.	Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US10919914B2 (en)	2016-06-08	2021-02-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US10561660B2 (en) *	2016-06-21	2020-02-18	Nerviano Medical Sciences S.R.L.	N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors
TW201811795A (zh)	2016-08-24	2018-04-01	美商亞闊股份有限公司	胺基－吡咯并嘧啶酮化合物及其用途
WO2018111902A1 (en)	2016-12-12	2018-06-21	Multivir Inc.	Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
EP3740468B1 (en)	2018-01-20	2025-12-31	Sunshine Lake Pharma Co., Ltd.	Substituted Aminopyrimidine Compounds and Methods of Use
CN112020510B (zh)	2018-03-19	2024-10-11	茂体外尔公司	包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物
WO2021113644A1 (en)	2019-12-05	2021-06-10	Multivir Inc.	Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
CN115989223B (zh) *	2020-07-03	2024-09-20	南京艾美斐生物医药科技有限公司	使用CCR8抑制剂靶向Tregs的方法和组合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2527754T3 (es)	2000-04-25	2015-01-29	Icos Corporation	Inhibidores de la isoforma delta de la fosfatidilinositol 3-quinasa humana
US6667300B2 (en)	2000-04-25	2003-12-23	Icos Corporation	Inhibitors of human phosphatidylinositol 3-kinase delta
TW200407143A (en)	2002-05-21	2004-05-16	Bristol Myers Squibb Co	Pyrrolotriazinone compounds and their use to treat diseases
US6752411B2 (en)	2002-06-24	2004-06-22	Norco Industries, Inc.	Multi-stage torsion axle
TW200400816A (en)	2002-06-26	2004-01-16	Lilly Co Eli	Tricyclic steroid hormone nuclear receptor modulators
KR20060022647A (ko)	2003-04-25	2006-03-10	길리애드 사이언시즈, 인코포레이티드	키나아제 억제 포스포네이트 유사체
US20050043239A1 (en)	2003-08-14	2005-02-24	Jason Douangpanya	Methods of inhibiting immune responses stimulated by an endogenous factor
LT2612862T (lt) *	2004-05-13	2017-01-25	Icos Corporation	Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
DK200400182U4 (da)	2004-06-23	2005-10-14	Alfa Laval Tank Equipment As	Drivenhed især til brug i forbindelse med tankrenseudstyr
GB0417709D0 (en)	2004-08-09	2004-09-08	Glaxo Group Ltd	Compounds
BRPI0615233A2 (pt)	2005-08-26	2011-05-10	Serono Lab	derivados de pirazina e uso dos mesmos como inibidores p13k
EP1931642A4 (en)	2005-09-15	2011-06-01	Orchid Res Lab Ltd	NEW PYRIMIDINE CARBOXAMIDES
US7525866B2 (en)	2006-04-19	2009-04-28	Freescale Semiconductor, Inc.	Memory circuit
FI20065449A0 (fi)	2006-06-29	2006-06-29	Nokia Corp	Tehonkulutuksen valvontamenetelmä, tehonkulutuksen valvontalaite, tietokoneohjelmatuote, tietokoneohjelman jakeluväline ja kommunikaatioväline
TW200840581A (en)	2007-02-28	2008-10-16	Astrazeneca Ab	Novel pyrimidine derivatives
UY31137A1 (es)	2007-06-14	2009-01-05	Smithkline Beecham Corp	Derivados de quinazolina como inhibidores de la pi3 quinasa
ITRN20070034A1 (it)	2007-06-27	2008-12-28	Sica Spa	Macchina e metodo di taglio di un tubo estruso in continuo in spezzoni di minore e predeterminata lunghezza.
TWI441601B (zh)	2007-06-28	2014-06-21	Philip Morris Products Sa	具有高白堊含量之圖案化包裝紙
US20100286145A1 (en)	2007-07-26	2010-11-11	Comentis, Inc.	Isophthalamide derivatives inhibiting beta-secretase activity
EP2300437B1 (en)	2008-06-05	2013-11-20	Glaxo Group Limited	Benzpyrazol derivatives as inhibitors of pi3 kinases
US20110212053A1 (en)	2008-06-19	2011-09-01	Dapeng Qian	Phosphatidylinositol 3 kinase inhibitors
MX2011009955A (es)	2009-03-24	2011-11-18	Gilead Calistoga Llc	Atropisomeros de derivados de 2-purinil-3-tolil-quinazolinona y metodos de uso.
CA2763692A1 (en)	2009-07-02	2011-01-06	Merz Pharma Gmbh & Co. Kgaa	Neurotoxins exhibiting shortened biological activity
WO2011058109A1 (en) *	2009-11-12	2011-05-19	Ucb Pharma S.A.	Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors
WO2011119704A1 (en)	2010-03-23	2011-09-29	Glaxosmithkline Llc	Trpv4 antagonists
CN103002738A (zh) *	2010-05-21	2013-03-27	英特利凯恩有限责任公司	用于激酶调节的化学化合物、组合物和方法
EP2394998A1 (en)	2010-05-31	2011-12-14	Almirall, S.A.	3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
WO2012000202A1 (zh)	2010-07-02	2012-01-05	Tsai Wen-Kai	人员派遣事务机及其应用的人员派遣方法
CN103209960A (zh)	2010-07-26	2013-07-17	百时美施贵宝公司	用作cyp17抑制剂的磺酰胺化合物
US9006449B2 (en)	2010-07-29	2015-04-14	Oryzon Genomics, S.A.	Cyclopropylamine derivatives useful as LSD1 inhibitors
EP2699257A4 (en)	2011-04-21	2014-10-15	Univ Louisiana State	PEPTIDE AND CONJUGATE VACCINES FOR FUNGI INFECTIONS
EP2518070A1 (en) *	2011-04-29	2012-10-31	Almirall, S.A.	Pyrrolotriazinone derivatives as PI3K inhibitors
CN102229416B (zh)	2011-06-29	2013-06-05	三一汽车起重机械有限公司	一种起重机闭式回转液压系统及起重机
WO2013040059A1 (en)	2011-09-12	2013-03-21	Merck Patent Gmbh	Novel imidazole amines as modulators of kinase activity
WO2014015523A1 (en)	2012-07-27	2014-01-30	Hutchison Medipharma Limited	Novel heteroaryl and heterocycle compounds, compositions and methods

2013
- 2013-10-15 CA CA2883426A patent/CA2883426A1/en not_active Abandoned
- 2013-10-15 US US14/435,851 patent/US9388189B2/en not_active Expired - Fee Related
- 2013-10-15 BR BR112015007231A patent/BR112015007231A2/pt not_active IP Right Cessation
- 2013-10-15 SG SG11201502032VA patent/SG11201502032VA/en unknown
- 2013-10-15 EA EA201500426A patent/EA027277B1/ru not_active IP Right Cessation
- 2013-10-15 HK HK15111815.3A patent/HK1211027A1/xx unknown
- 2013-10-15 AU AU2013333938A patent/AU2013333938A1/en not_active Abandoned
- 2013-10-15 AP AP2015008328A patent/AP2015008328A0/xx unknown
- 2013-10-15 JP JP2015537230A patent/JP2015533181A/ja not_active Withdrawn
- 2013-10-15 PE PE2015000410A patent/PE20150637A1/es not_active Application Discontinuation
- 2013-10-15 MD MDA20150048A patent/MD20150048A2/ro not_active Application Discontinuation
- 2013-10-15 MX MX2015004327A patent/MX2015004327A/es unknown
- 2013-10-15 GE GEAP201313828A patent/GEP201706623B/en unknown
- 2013-10-15 EP EP13779788.2A patent/EP2909207A1/en not_active Withdrawn
- 2013-10-15 CN CN201380065926.2A patent/CN104854108A/zh active Pending
- 2013-10-15 KR KR1020157009063A patent/KR20150068953A/ko not_active Withdrawn
- 2013-10-15 WO PCT/EP2013/071551 patent/WO2014060432A1/en not_active Ceased
- 2013-10-16 TW TW102137293A patent/TW201429975A/zh unknown
- 2013-10-16 AR ARP130103757A patent/AR093036A1/es unknown
- 2013-10-16 UY UY0001035086A patent/UY35086A/es not_active Application Discontinuation
2015
- 2015-02-23 ZA ZA2015/01220A patent/ZA201501220B/en unknown
- 2015-02-26 IL IL237475A patent/IL237475A0/en unknown
- 2015-03-24 TN TNP2015000112A patent/TN2015000112A1/fr unknown
- 2015-03-30 CR CR20150175A patent/CR20150175A/es unknown
- 2015-03-30 DO DO2015000077A patent/DOP2015000077A/es unknown
- 2015-04-13 PH PH12015500813A patent/PH12015500813A1/en unknown
- 2015-04-15 CL CL2015000956A patent/CL2015000956A1/es unknown
- 2015-04-16 NI NI201500054AA patent/NI201500054A/es unknown
- 2015-04-16 GT GT201500094A patent/GT201500094A/es unknown

Also Published As

Publication number	Publication date
TW201429975A (zh)	2014-08-01
IL237475A0 (en)	2015-04-30
AU2013333938A1 (en)	2015-04-09
EP2909207A1 (en)	2015-08-26
EA027277B1 (ru)	2017-07-31
MX2015004327A (es)	2015-06-10
NI201500054A (es)	2016-02-01
CN104854108A (zh)	2015-08-19
AP2015008328A0 (en)	2015-03-31
CA2883426A1 (en)	2014-04-24
MD20150048A2 (ro)	2015-10-31
BR112015007231A2 (pt)	2017-07-04
PH12015500813B1 (en)	2015-06-08
PE20150637A1 (es)	2015-05-08
TN2015000112A1 (en)	2016-06-29
GT201500094A (es)	2017-08-01
AR093036A1 (es)	2015-05-13
WO2014060432A1 (en)	2014-04-24
PH12015500813A1 (en)	2015-06-08
UY35086A (es)	2014-05-30
DOP2015000077A (es)	2015-04-30
ZA201501220B (en)	2017-04-26
KR20150068953A (ko)	2015-06-22
EA201500426A1 (ru)	2015-10-30
SG11201502032VA (en)	2015-05-28
US20150291595A1 (en)	2015-10-15
GEP201706623B (en)	2017-02-10
JP2015533181A (ja)	2015-11-19
CL2015000956A1 (es)	2015-06-19
US9388189B2 (en)	2016-07-12
CR20150175A (es)	2015-05-11

Publication	Publication Date	Title
HK1211027A1 (en)	2016-05-13	Pyrrolotriazinone derivatives as pi3k inhibitors
MY171553A (en)	2019-10-18	Pyrrolotriazinone derivatives as pi3k inhibitors
PH12012502334A1 (en)	2013-02-11	Heteroaryl imidazolone derivatives as jak inhibitors
PH12012501164A1 (en)	2017-08-23	Imidazopyridine derivatives as jak inhibitors
PH12014500103A1 (en)	2019-03-22	Pyridin-2(1h)-one derivatives as jak inhibitors
MX2015010858A (es)	2015-12-03	Formas solidas de un inhbidor de cdk4/6 selectivo.
PH12014501542B1 (en)	2014-09-22	Substituted pyrrolidine -2- carboxamides
IL231226A (en)	2017-03-30	Compounds and preparations as kinase c-kit inhibitors, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of diseases
MX352927B (es)	2017-12-14	Derivados de 1h-pirrolo [2,3-b] piridina y su uso como inhibidores de quinasa.
PH12013500742A1 (en)	2015-10-23	Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as jak inhibitors
MX336381B (es)	2016-01-18	Boronatos como inhibidores de arginasa.
MX2012002876A (es)	2012-04-20	Derivados de dihidropteridinona, proceso para su preparacion y uso farmaceutico.
WO2012104007A3 (de)	2013-10-17	7-azaindolderivate
WO2013004995A8 (en)	2013-03-07	Pyrimidinone compounds and their use
EA201590183A1 (ru)	2015-06-30	Производные азаиндола, выступающие в качестве ингибиторов pi3k
IN2015DN00950A (xx)	2015-06-12
WO2012136080A8 (zh)	2013-10-24	苯并吗啉衍生物及其制备方法和应用
MX2013005624A (es)	2013-07-05	Nuevos derivados de indolizina, su preparacion y su aplicacion en terapeutica.
HK1178527A (en)	2013-09-13	Heteroaryl imidazolone derivatives as jak inhibitors
ECSP15015088A (es)	2015-12-31	Derivados de pirrolotriazinona como inhibidores de pi3k
HK1172905A (en)	2013-05-03	Pyrazole derivatives as jak inhibitors
HK1170730A (en)	2013-03-08	Imidazopyridine derivatives as jak inhibitors